Paul A. Beales

This study modifies the membranolytic peptide MP1 with EGFR-binding and MMP-2 cleavage sequences to target cancer cells, showing reduced toxicity and tumor growth in vivo.

The paper identifies MP-1 peptide mutants with enhanced selectivity for cancer-like membranes and breast cancer cells, revealing structure-activity relationships through model membranes and cell assays.

The paper demonstrates that membrane tension, regulated by ILV formation, negatively feedbacks to control ESCRT-III activity in vitro, with potential implications for in vivo functions.